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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. It discusses the aetiology and risk factors for head and neck cancer and the recommended
interventions appropriate for each risk factor.
Recommendations
• Recent evidence synthesis from National Institute for Health and Care Excellence suggests that the following brief inter-
ventions for smoking cessation work should be used:
○ Ask smokers how interested they are in quitting (R)
○ If they want to stop, refer them to an intensive support service such as National Health Service Stop Smoking Services (R)
○ If they are unwilling or unable to accept a referral, offer a stop smoking aid, e.g. pharmacotherapy. (R)
• Brief interventions are effective for hazardous and harmful drinking. (R)
• Specialist interventions are effective in people with alcohol dependence. (R)
• Most people with alcohol dependence can undergo medically assisted withdrawal safely at home, after risk assessment. (R)
• Management of leukoplakia is not informed by high-level evidence but consensus supports targeted use of biopsy and histo-
pathological assessment. (R)
• The management of biopsy proven dysplastic lesions favours:
○ advice to reduce known environmental carcinogens such as tobacco and alcohol (R)
○ surgical excision when the size of the lesions and the patient’s function allows (R)
○ long-term surveillance. (R)
• Fanconi anaemia patients should:
○ be followed up in a multidisciplinary specialist Fanconi anaemia clinic (G)
○ have quarterly screening for head and neck squamous cell carcinoma and an aggressive biopsy policy (G)
○ receive prophylactic vaccination against high risk human papilloma virus (G)
○ receive treatment for head and neck squamous cell carcinoma with surgery alone where possible. (G)
Introduction
The major risk factors for head and neck cancer in the
UK are tobacco smoking and alcohol consumption
and withdrawal of these environmental carcinogens
remains the focus for primary and secondary prevention.
Additionally the role of human papilloma virus (HPV) is
being increasingly recognised, but as the natural history
and transmission of oral and oropharyngeal HPV infec-
tion are incompletely understood, the opportunities for
reducing this risk are not yet clear. Some patients have
recognised local or systemic pre-malignant conditions
which are also discussed.
Smoking
Smoking is an independent risk factor for head and
neck cancer.1 Patients who continue to smoke during
radiotherapy are more likely to develop osteo-
radionecrosis and to require hospitalisation during
treatment. Continued smoking through radiotherapy
was thought to have an adverse effect on local
control (hazard ratio 1.5) and survival (hazard ratio
1.7), but more recent evidence would suggest baseline
smoking status is more important.2 Smoking cessation
before surgery is desirable to reduce the risk of anaes-
thetic related complications and improve wound
healing, particularly after reconstructive surgery.3,4
Quitting tobacco smoking for a short period of time
(one to four years) results in a head and neck cancer
risk reduction of about 30 per cent compared with
current smoking, reduces the risk of laryngeal cancer
by 60 per cent after 10–15 years and after 20 years
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can reduce the risk of developing oral cavity cancer to
the level of a never smoker.5
Recommendations
• Recent evidence from NICE suggests that the
following brief interventions for smoking
cessation work should be used:
○ Ask smokers how interested they are in
quitting (R)
○ If they want to stop, refer them to an
intensive support service such as NHS Stop
Smoking Services (R)
○ If they are unwilling or unable to accept a
referral, offer a stop smoking aid, e.g.
pharmacotherapy (R)
Alcohol
Alcohol is the other major independent risk factor for
head and neck cancer. Patients who continue to drink
heavily after treatment for head and neck cancer have
a significantly worse quality of life6 and continued
drinking has a negative impact on survival (hazard
ratio 1.28).7,8 The beneficial effects of quitting
alcohol, on the risk of developing head and neck
cancer, are only observed after more than 20 years,
when the level of risk reaches that of non-drinkers.5
Cessation of alcohol on admission for surgery can
present a significant problem in heavy drinkers. A
review in the British Medical Journal suggests that
we should screen all patients for excessive alcohol con-
sumption with a validated questionnaire such as Fast
Alcohol Screening Test.9
Recommendations
• Brief interventions are effective for hazardous
and harmful drinking (R)
• Specialist interventions are effective in people
with alcohol dependence (R)
• Most people with alcohol dependence can
undergo medically assisted withdrawal safely
at home, after risk assessment (R)
Human papilloma virus
Human papilloma virus -16 is an increasingly relevant
causative agent in oropharyngeal and oral squamous
cell carcinoma (SCC), however doubt remains in
other sites and for other HPV subtypes. Combined
data from recently published (2006–2009) studies
shows that 55 per cent of 654 oropharyngeal SCC
cases were HPV-16 positive.10 The prevalence of
HPV-16 chronic infection in oropharyngeal mucosa
of the general population is currently unclear.
Without a clinically identifiable premalignant lesion,
any future (primary or secondary) screening approach
would rely on molecular biomarkers. Oral HPV infec-
tion increases with numbers of recent oral sex partners
and isolated cases of transmission of HPV-16 between
partners leading to the possible ‘transmission’ of
cancer have been reported.11 Evidence seems currently
insufficient to counsel avoidance of specific sexual
activities, over and above guidance that informs the
prevention of other sexually transmitted diseases. It is
awaited with interest as to whether the current pro-
gramme of vaccination against high risk HPV (strains
16 and 18) offered to 12–13-year-old girls will in the
future reduce the incidence of head and neck squamous
cell carcinoma (HNSCC).
Premalignant lesions
Leukoplakia and erythroplakia are common premalig-
nant lesions; however, most HNSCC cases have no
history of such antecedent lesions. Biopsy-proven epi-
thelial dysplasia is demonstrated in 25 per cent of biop-
sies of leukoplakia but most erythroplakia; however,
HPV-16 is very rarely a factor in these conditions.
The significant clinical predictors of malignant trans-
formation in oral dysplastic lesions are non-smoking
status, sub-site (e.g., high risk in lateral tongue and
low risk in floor of mouth), non-homogeneous appear-
ance, size of lesion greater than 200 mm and higher
histological grade (severe vs mild/moderate). A
recent systematic review of oral dysplasia (992
patients) showed malignant transformation in 12.1 per
cent after mean 4.3 years following biopsy.12 Severity
of dysplasia predicted for malignant transformation
(p= 0.008). Lesions that were not excised demon-
strated considerably higher transformation rate than
those that were excised (p= 0.003).13 A binary histo-
logical grading into the high and low risks has been
suggested based on good predictive power that has
been independently verified in other series. A system-
atic review of laryngeal dysplastic lesions (942
patients) showed transformation in 14 per cent after a
mean interval of 5.8 years, again severity of dysplasia
correlated with risk of transformation.14
Importantly, these data only reflect patients already
referred for a specialist opinion and with biopsy-
proven dysplasia. In population-based studies of oral
leukoplakia without histological inclusion criteria the
risks are much lower; 40–50 per cent regress spontan-
eously and less than 1 per cent transform.15,16 There is
insufficient evidence to justify screening in the general
population to prevent oral cancer.17
The premalignant potential of oral lichen planus
(OLP) is controversial; however, rigorously conducted
retrospective series have confirmed the risk in classic
inflammatory OLP with histological confirmation is
low, at about 1 per cent. Oral lichenoid lesions which
harbour features of OLP, but also epithelial dysplasia
do present a modest risk for malignant transformation,
and in some series this subset reflect the only cancer
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cases arising, interestingly with a predisposition to
lateral tongue. Proliferative verrucous leukoplakia is a
rare condition presenting with exophytic widespread
progressive leukoplakia, somewhat refractory to inter-
vention and with very high (50–80 per cent) transform-
ation rates and hence, poor overall prognosis.
Recommendations
• Management of leukoplakia is not informed
by high-level evidence, but consensus
supports targeted use of biopsy and
histopathological assessment (R)
• The management of biopsy proven dysplastic
lesions favours:
○ advice to reduce known environmental
carcinogens such as tobacco and alcohol
(R)
○ surgical excision when the size of the
lesions and the patient’s function allows
(R)
○ long-term surveillance (R)
Premalignant conditions
Inherited
Inherited conditions with increased risk of HNSCC
include Fanconi anaemia (FA), ataxia telangiectasia,
Bloom’s syndrome and Li–Fraumeni syndrome.
Fanconi anaemia has a very high risk of developing
HNSCC (particularly oropharyngeal squamous cell
carcinoma), most notably after haematopoietic stem
cell transplantation.18 Recent evidence suggests a
possibility that HPV may be implicated in FA-related
oropharyngeal squamous cell carcinoma.19 Fanconi
anaemia patients do not tolerate cisplatin and have
severe toxicity with radiotherapy. Life expectancy has
improved so that the population at risk for HNSCC is
greater. Head and neck squamous cell carcinoma can
occur early in patients as young as 11 years old.
Further guidance is available from http://www.fanco-
nianaemia.nhs.uk
Recommendation
• Fanconi anaemia patients should:
○ be followed up in a multidisciplinary
specialist FA clinic (G)
○ have quarterly screening for HNSCC and
an aggressive biopsy policy (G)
○ receive prophylactic vaccination against
high risk HPV (G)
○ receive treatment for HNSCC with surgery
alone where possible
Acquired immunodeficiency
Patients who are immunosuppressed due to poor nutri-
tion, advanced age, immunosuppressive therapy after
transplant or acquired immunodeficiency syndrome
(AIDS) are at greater risk of developing malignancy.
The most commonly reported AIDS-related neoplasms
of the head and neck region include Kaposi’s sarcoma
and non-Hodgkin’s lymphoma. There is also an
increased risk of oropharyngeal squamous cell carcin-
oma. Although HPV-related HNSCC has been seen
in immunosuppressed patients, further clinical studies
are needed to determine the safety and effectiveness
of HPV vaccines in this setting.
Key points
• Smoking is an independent risk factor for head
and neck cancer, is associated with post treatment
complications and has an adverse effect on onco-
logical outcomes
• Alcohol is an independent risk factor for head and
neck cancer and continued drinking has a negative
impact on survival
• High risk human papilloma viruses (HPV 16 and
18) are recognised causative agents for oropharyn-
geal squamous cell carcinoma
• Malignant transformation of oral dysplasia and
laryngeal dysplasia occurs in 12 per cent (mean
4.3 years) and in 14 percent (mean 5.8 years)
respectively.
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